View Item 

Show simple item record

Meeting the Challenge to Improve the Treatment of Hypertension in Blacks
dc.contributor.authorLopes, Antonio Albertoen_US
dc.contributor.authorJames, Sherman A.en_US
dc.contributor.authorPort, Friedrich K.en_US
dc.contributor.authorOjo, Akinlolu O.en_US
dc.contributor.authorAgodoa, Lawrence Y.en_US
dc.contributor.authorJamerson, Kenneth A.en_US
dc.date.accessioned2010-06-01T22:01:59Z
dc.date.available2010-06-01T22:01:59Z
dc.date.issued2003-11en_US
dc.identifier.citationLopes, Antonio Alberto; James, Sherman A.; Port, Friedrich K.; Ojo, Akinlolu O.; Agodoa, Lawrence Y.; Jamerson, Kenneth A. (2003). "Meeting the Challenge to Improve the Treatment of Hypertension in Blacks." The Journal of Clinical Hypertension 5(6): 393-401. <http://hdl.handle.net/2027.42/75060>en_US
dc.identifier.issn1524-6175en_US
dc.identifier.issn1751-7176en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75060
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14688494&dopt=citationen_US
dc.format.extent1230688 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherLe Jacq Communications, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2003 Le Jacq Communications, Inc.en_US
dc.titleMeeting the Challenge to Improve the Treatment of Hypertension in Blacksen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartments of Epidemiology and Health Behavior and Health Education, University of Michigan, Ann Arbor, MI;en_US
dc.contributor.affiliationumDivision of Nephrology, University of Michigan, Ann Arbor, MI;en_US
dc.contributor.affiliationumDivision of Hypertension and Hyperlipidemia, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherFrom the Department of Medicine, Federal University of Bahia, Brazil;en_US
dc.contributor.affiliationotherUniversity Renal Research and Education Association (URREA), Ann Arbor, MI;en_US
dc.contributor.affiliationotherNational Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD;en_US
dc.identifier.pmid14688494en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75060/1/j.1524-6175.2003.01736.x.pdf
dc.identifier.doi10.1111/j.1524-6175.2003.01736.xen_US
dc.identifier.sourceThe Journal of Clinical Hypertensionen_US
dc.identifier.citedreference1 HDFP Cooperative group. Blood pressure studies in 14 communities. A two-stage screen for hypertension. JAMA. 1977; 237: 2385 – 2391.en_US
dc.identifier.citedreferenceLopes AA. HipertensÃo arterial: fatores Étnicos e raciais. J Bras Nefrol. 1999; 21: 82 – 84.en_US
dc.identifier.citedreferenceLopes AA, Port FK, James SA, et al. The excess risk of treated end-stage renal disease in blacks in the United States. J Am Soc Nephrol. 1993; 3: 1961 – 1971.en_US
dc.identifier.citedreferenceKittner SJ, White LR, Losonczy KG, et al. Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. JAMA. 1990; 264: 1267 – 1270.en_US
dc.identifier.citedreferenceKoren MJ, Mensah GA, Blake J, et al. Comparison of left ventricular mass and geometry in black and white patients with essential hypertension. Am J Hypertens. 1993; 6: 815 – 823.en_US
dc.identifier.citedreferenceMilne FJ, James SH, Veriava Y. Malignant hypertension and its renal complications in black South Africans. S Afr Med J. 1989; 76: 164 – 167.en_US
dc.identifier.citedreferenceRamos O. Malignant hypertension: the Brazilian experience. Kidney Int. 1984; 26: 209 – 217.en_US
dc.identifier.citedreferencePrimatesta P, Bost L, Poulter NR. Blood pressure levels and hypertension status among ethnic groups in England. J Hum Hypertens. 2000; 14: 143 – 148.en_US
dc.identifier.citedreferenceRibeiro MB, Ribeiro AB, Neto CS, et al. Hypertension and economic activities in Sao Paulo, Brazil. Hypertension. 1981; 3: II233 – II237.en_US
dc.identifier.citedreferenceJames SA, De Almeida-Filho N, Kaufman JS. Hypertension in Brazil: a review of the epidemiological evidence. Ethn Dis. 1991; 1: 91 – 98.en_US
dc.identifier.citedreferenceMoser M, Morgan R, Hale M, et al. Epidemiology of hypertension with particular reference to the Bahamas, Part I: preliminary report of blood pressure and possible etiologic factors. Am J Cardiol. 1959; 4: 727 – 733.en_US
dc.identifier.citedreferenceAscherio A, Hennekens C, Willett WC, et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension. 1996; 27: 1065 – 1072.en_US
dc.identifier.citedreferenceMarmot MG, Elliott P, Shipley MJ, et al. Alcohol and blood pressure: the INTERSALT study. BMJ. 1994; 308: 1263 – 1267.en_US
dc.identifier.citedreferenceNeser WB, Thomas J, Semenya K, et al. Obesity and hypertension in a longitudinal study of black physicians: the Meharry Cohort Study. J Chronic Dis. 1986; 39: 105 – 113.en_US
dc.identifier.citedreferenceAinsworth BE, Keenan NL, Strogatz DS, et al. Physical activity and hypertension in black adults: the Pitt County Study. Am J Public Health. 1991; 81: 1477 – 1479.en_US
dc.identifier.citedreferenceKumanyika S. Obesity in black women. Epidemiol Rev. 1987; 9: 31 – 50.en_US
dc.identifier.citedreference17 Veterans Administration Cooperative Study Group on Antihypertensive Agents. Urinary and serum electrolytes in untreated black and white hypertensives. J Chronic Dis. 1987; 40: 839 – 847.en_US
dc.identifier.citedreferenceSvetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med. 1999; 159: 285 – 293.en_US
dc.identifier.citedreferenceVollmer WM, Svetkey LP, Appel LJ, et al. Recruitment and retention of minority participants in the DASH controlled feeding trial. DASH Collaborative Research Group. Dietary Approaches to Stop Hypertension. Ethn Dis. 1998; 8: 198 – 208.en_US
dc.identifier.citedreferenceBeard TC, Cooke HM, Gray WR, et al. Randomised controlled trial of a no-added-sodium diet for mild hypertension. Lancet. 1982; 2: 455 – 458.en_US
dc.identifier.citedreferenceSinger DR, Markandu ND, Cappuccio FP, et al. Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide. Hypertension. 1995; 25: 1042 – 1044.en_US
dc.identifier.citedreferenceSacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001; 344: 3 – 10.en_US
dc.identifier.citedreferenceBrancati FL, Appel LJ, Seidler AJ, et al. Effect of potassium supplementation on blood pressure in African Americans on a lowpotassium diet. A randomized, double-blind, placebo-controlled trial. Arch Intern Med. 1996; 156: 61 – 67.en_US
dc.identifier.citedreferenceSudhir K, Forman A, Yi SL, et al. Reduced dietary potassium reversibly enhances vasopressor response to stress in African Americans. Hypertension. 1997; 29: 1083 – 1090.en_US
dc.identifier.citedreference25 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report. Arch Intern Med. 1997; 157: 2413 – 2446.en_US
dc.identifier.citedreferenceKokkinos PF, Narayan P, Colleran JA, et al. Effects of regular exercise on blood pressure and left ventricular hypertrophy in African-American men with severe hypertension. N Engl J Med. 1995; 333: 1462 – 1467.en_US
dc.identifier.citedreferenceBarnes VA, Treiber FA, Davis H. Impact of transcendental meditation on cardiovascular function at rest and during acute stress in adolescents with high normal blood pressure. J Psychosom Res. 2001; 51: 597 – 605.en_US
dc.identifier.citedreferenceSchneider RH, Staggers F, Alxander CN, et al. A randomised controlled trial of stress reduction for hypertension in older African Americans. Hypertension. 1995; 26: 820 – 827.en_US
dc.identifier.citedreferenceCurtis AB, James SA, Strogatz DS, et al. Alcohol consumption and changes in blood pressure among African Americans. The Pitt County Study. Am J Epidemiol. 1997; 146: 727 – 733.en_US
dc.identifier.citedreferenceFuchs FD, Chambless LE, Whelton PK, et al. Alcohol consumption and the incidence of hypertension: the Atherosclerosis Risk in Communities Study. Hypertension. 2001; 37: 1242 – 1250.en_US
dc.identifier.citedreferenceXin X, He J, Frontini MG, et al. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension. 2001; 38: 1112 – 1117.en_US
dc.identifier.citedreferenceDavis BR, Blaufox MD, Oberman A, et al. Reduction in longterm antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med. 1993; 153: 1773 – 1782.en_US
dc.identifier.citedreferenceJones DW, Miller ME, Wofford MR, et al. The effect of weight loss intervention on antihypertensive medication requirements in the Hypertension Optimal Treatment (HOT) study. Am J Hypertens. 1999; 12: 1175 – 1180.en_US
dc.identifier.citedreference34 Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to lowdose captopril are abolished by the addition of hydrochlorothiazide. Br J Clin Pharmacol. 1982; 14: 97S – 101S.en_US
dc.identifier.citedreferencePrisant LM, Mensah GA. Use of beta-adrenergic receptor blockers in blacks. J Clin Pharmacol. 1996; 36: 867 – 873.en_US
dc.identifier.citedreferenceHansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999; 353: 611 – 616.en_US
dc.identifier.citedreferenceBrown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a longacting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000; 356: 366 – 372.en_US
dc.identifier.citedreferenceHansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000; 356: 359 – 365.en_US
dc.identifier.citedreferenceLindholm LH, Hansson L, Ekbom T, et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens. 2000; 18: 1671 – 1675.en_US
dc.identifier.citedreferenceAgodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001; 285: 2719 – 2728.en_US
dc.identifier.citedreferenceWright JT Jr, Bakris G, Green T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002; 288: 2421 – 2431.en_US
dc.identifier.citedreference42 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the hypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000; 283: 1967 – 1975.en_US
dc.identifier.citedreference43 The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002; 288: 2981 – 2995.en_US
dc.identifier.citedreference44 National Center for Health Statistics. Prevalence of Diagnosed Diabetes, Undiagnosed Diabetes, and Impaired Glucose Tolerance in Adults 20–74 Years of Age, United States, 1976–1980. Vital and Health Statistics. Series 11, No. 237. DHHS Pub. No. (PHS) 87-1687. Public Health Service. Washington, DC: US Government Printing Office; 1987.en_US
dc.identifier.citedreferenceLopes AA, Port FK. Differences in the patterns of age-specific black/white comparisons between end-stage renal disease attributed and not attributed to diabetes. Am J Kidney Dis. 1995; 25: 714 – 721.en_US
dc.identifier.citedreferenceChaiken RL, Palmisano J, Norton ME, et al. Interaction of hypertension and diabetes on renal function in black NIDDM subjects. Kidney Int. 1995; 47: 1697 – 1702.en_US
dc.identifier.citedreferenceViberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 1994; 271: 275 – 279.en_US
dc.identifier.citedreference48 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000; 355: 253 – 259.en_US
dc.identifier.citedreference49 UK Prospective Diabetes Study group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998; 317: 713 – 720.en_US
dc.identifier.citedreferenceParving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001; 345: 870 – 878.en_US
dc.identifier.citedreferenceBrenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861 – 869.en_US
dc.identifier.citedreferenceLewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345: 851 – 860.en_US
dc.identifier.citedreferenceHansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 1755 – 1762.en_US
dc.identifier.citedreferenceEstacio RO, Jeffers BW, Gifford N, et al. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000; 23 ( Suppl 2 ): B54 – B64.en_US
dc.identifier.citedreference55 UK Prospective Diabetes Study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998; 317: 703 – 713.en_US
dc.identifier.citedreferenceLopes AA, Andrade J, Noblat AC, et al. Reduction in diastolic blood pressure and cardiovascular mortality in nondiabetic hypertensive patients. A reanalysis of the HOT study. Arq Bras Cardiol. 2001; 77: 132 – 137.en_US
dc.identifier.citedreferenceShea S, Misra D, Ehrlich MH, et al. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med. 1992; 327: 776 – 781.en_US
dc.identifier.citedreferenceNobre F, Chauchar F, Viana JM, et al. Evaluation of the medical care of patients with hypertension in an emergency department and in ambulatory hypertension unit. Arq Bras Cardiol. 2002; 78: 159 – 161.en_US
dc.identifier.citedreferenceOoi WL, Budner NS, Cohen H, et al. Impact of race on treatment response and cardiovascular disease among hypertensives. Hypertension. 1989; 14: 227 – 234.en_US
dc.identifier.citedreferenceWalker WG, Neaton JD, Cutler JA, et al. Renal function change in hypertensive members of the Multiple Risk Factor Intervention Trial. Racial and treatment effects. The MRFIT Research Group. JAMA. 1992; 268: 3085 – 3091.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1524-6175.2003.01736.x.pdf
Size:
1.173MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.